What is Wall Street's Target Price for Forte Biosciences Inc (FBRX) Stock Monday?

Monday, August 15, 2022 01:27 PM | InvestorsObserver Analysts

Mentioned in this article

Wall Street is positive on Forte Biosciences Inc (FBRX). On average, analysts give the stock a Buy rating. The average price target is $3.5, which means analysts expect the stock to gain by 171.32% over the next twelve months. That average ranking earns the stock an Analyst Rating of 23, which is better than 23% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating FBRX a Buy today. Find out what this means to you and get the rest of the rankings on FBRX!
See Full FBRX Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Forte Biosciences Inc Stock Today?

Forte Biosciences Inc (FBRX) stock is lower by -3.01% while the S&P 500 is higher by 0.35% as of 1:26 PM on Monday, Aug 15. FBRX is down -$0.04 from the previous closing price of $1.33 on volume of 305,382 shares. Over the past year the S&P 500 is down -4.12% while FBRX is down -94.58%. FBRX lost -$1.37 per share the over the last 12 months. Click Here to get the full Stock Report for Forte Biosciences Inc stock.

Share this article:

Related Articles